PE20151144A1 - Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias - Google Patents
Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatoriasInfo
- Publication number
- PE20151144A1 PE20151144A1 PE2015000712A PE2015000712A PE20151144A1 PE 20151144 A1 PE20151144 A1 PE 20151144A1 PE 2015000712 A PE2015000712 A PE 2015000712A PE 2015000712 A PE2015000712 A PE 2015000712A PE 20151144 A1 PE20151144 A1 PE 20151144A1
- Authority
- PE
- Peru
- Prior art keywords
- gamma
- modulators
- treatment
- alkyl
- ror
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- ZGUUFGJXZFLEFM-INIZCTEOSA-N n-[3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]-2-methylpyrimidine-5-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(F)=CC=1NC(=O)C1=CN=C(C)N=C1 ZGUUFGJXZFLEFM-INIZCTEOSA-N 0.000 abstract 2
- IQXNFWSDMOQEKD-SFHVURJKSA-N n-[5-chloro-3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(Cl)=CC=1NC(=O)C1=CC=C(C)N=C1 IQXNFWSDMOQEKD-SFHVURJKSA-N 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012001636 | 2012-12-06 | ||
| CN2013000182 | 2013-02-25 | ||
| CN2013000803 | 2013-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151144A1 true PE20151144A1 (es) | 2015-08-02 |
Family
ID=49709687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000712A PE20151144A1 (es) | 2012-12-06 | 2013-12-05 | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias |
Country Status (33)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| WO2015180613A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| ES2716966T3 (es) * | 2014-05-28 | 2019-06-18 | Glaxosmithkline Ip Dev Ltd | Derivados de piperazina como moduladores de ROR-gamma |
| WO2015180612A1 (en) * | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| CN104292208A (zh) * | 2014-09-09 | 2015-01-21 | 上海师范大学 | 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法 |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TW201625588A (zh) * | 2014-11-05 | 2016-07-16 | 第一三共股份有限公司 | 環狀胺衍生物 |
| JP2018505878A (ja) * | 2015-01-30 | 2018-03-01 | ファイザー・インク | Ｒｏｒｃ２のメトキシ置換ピロロピリジンモジュレーターならびにその使用方法 |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| EP3868750A1 (en) * | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| RU2771280C2 (ru) * | 2016-07-13 | 2022-04-29 | Лео Фарма А/С | Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| US11001552B2 (en) | 2017-07-18 | 2021-05-11 | Lonza Ltd | Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| CN108752185A (zh) * | 2018-07-17 | 2018-11-06 | 成都道合尔医药技术有限公司 | 一种1-氟-环戊甲酸的合成方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| CN110862319A (zh) * | 2019-12-04 | 2020-03-06 | 深圳振强生物技术有限公司 | 奥扎格雷杂质的制备方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) * | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| WO2012147916A1 (ja) | 2011-04-28 | 2012-11-01 | 日本たばこ産業株式会社 | アミド化合物およびその医薬用途 |
| WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| SG11201400456RA (en) | 2011-09-09 | 2014-04-28 | Univ New York | Amido compounds as ror?tmodulators and uses thereof |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| PE20142400A1 (es) | 2012-04-27 | 2015-02-04 | Glaxo Group Ltd | Compuestos novedosos |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
| KR20160068799A (ko) | 2013-10-25 | 2016-06-15 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| ES2716966T3 (es) | 2014-05-28 | 2019-06-18 | Glaxosmithkline Ip Dev Ltd | Derivados de piperazina como moduladores de ROR-gamma |
| WO2015180612A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| WO2015180613A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
-
2013
- 2013-12-05 SI SI201330650A patent/SI2928885T1/sl unknown
- 2013-12-05 ME MEP-2017-117A patent/ME02696B/me unknown
- 2013-12-05 PT PT137993184T patent/PT2928885T/pt unknown
- 2013-12-05 LT LTEP13799318.4T patent/LT2928885T/lt unknown
- 2013-12-05 TW TW102144579A patent/TW201427959A/zh unknown
- 2013-12-05 AU AU2013354109A patent/AU2013354109B2/en not_active Ceased
- 2013-12-05 EA EA201591059A patent/EA026437B1/ru not_active IP Right Cessation
- 2013-12-05 MX MX2015007180A patent/MX2015007180A/es unknown
- 2013-12-05 UY UY0001035174A patent/UY35174A/es unknown
- 2013-12-05 HU HUE13799318A patent/HUE033212T2/hu unknown
- 2013-12-05 SG SG11201504200TA patent/SG11201504200TA/en unknown
- 2013-12-05 PL PL13799318T patent/PL2928885T3/pl unknown
- 2013-12-05 BR BR112015013137-9A patent/BR112015013137B1/pt active IP Right Grant
- 2013-12-05 SM SM20170281T patent/SMT201700281T1/it unknown
- 2013-12-05 HR HRP20170638TT patent/HRP20170638T1/hr unknown
- 2013-12-05 AR ARP130104518A patent/AR093818A1/es unknown
- 2013-12-05 KR KR1020157017633A patent/KR20150092244A/ko not_active Ceased
- 2013-12-05 US US14/649,585 patent/US10005731B2/en not_active Expired - Fee Related
- 2013-12-05 ES ES13799318.4T patent/ES2626390T3/es active Active
- 2013-12-05 CA CA2894016A patent/CA2894016C/en active Active
- 2013-12-05 DK DK13799318.4T patent/DK2928885T3/en active
- 2013-12-05 PE PE2015000712A patent/PE20151144A1/es not_active Application Discontinuation
- 2013-12-05 RS RS20170372A patent/RS55875B1/sr unknown
- 2013-12-05 CN CN201380070619.3A patent/CN105121430B/zh active Active
- 2013-12-05 EP EP13799318.4A patent/EP2928885B1/en active Active
- 2013-12-05 JP JP2015546002A patent/JP6279605B2/ja not_active Expired - Fee Related
- 2013-12-05 WO PCT/EP2013/075594 patent/WO2014086894A1/en not_active Ceased
- 2013-12-05 EP EP17157475.9A patent/EP3219711A1/en not_active Withdrawn
-
2015
- 2015-05-22 ZA ZA2015/03666A patent/ZA201503666B/en unknown
- 2015-05-28 IL IL239082A patent/IL239082A0/en unknown
- 2015-06-02 PH PH12015501244A patent/PH12015501244A1/en unknown
- 2015-06-05 CL CL2015001557A patent/CL2015001557A1/es unknown
- 2015-06-08 CR CR20150302A patent/CR20150302A/es unknown
-
2017
- 2017-06-02 CY CY20171100587T patent/CY1118932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| SV2016005229A (es) | Inhibidores de syk | |
| CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| PE20180037A1 (es) | Nuevos derivados de piridina | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CR20140305A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| CO6351735A2 (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| UY35700A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| EA201791271A1 (ru) | ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ | |
| ECSP12011983A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| MX2017014621A (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma. | |
| CR20150302A (es) | Moduladores del receptor huérfano gamma relacionado a retinoide (ror-gamma) para uso en el tratamiento de enfermedades autoinmunes e inflamatorias | |
| MX386111B (es) | Compuestos nuevos como moduladores de ror gamma. | |
| UY36709A (es) | Moduladores de ror gamma (ror¿) | |
| ECSP15013883A (es) | Benzamidas | |
| PE20151536A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
| CL2015002202A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4. | |
| ECSP11011118A (es) | ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |